Molecular profiling as a predictor of treatment response and survival in unresectable pancreatic ductal adenocarcinoma.

• DOI: 10.1200/jco.2023.41.16_suppl.e16279
• Publication Date: 2023-06-04T15:38:35Z
• Authors: Rodrigo Paredes; Marcela Banegas; Santiago Sucre; Cristina Ponce; Ahmed Anwer Ali R...; Mary Linton Boune...
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

e16279 Background: To date, few targetable mutations have been found to enhance PDAC treatment. Next-generation sequencing (NGS) of somatic mutation profiles may help tailor cytotoxic chemotherapy selection and guide translational research. Methods: We analyzed NGS data from a retrospective cohort 142 patients with unresectable biopsy-proven August 2009 December 2022. Individual were grouped into 14 distinct signaling pathways: cell cycle, DNA damage repair, KIT, ErbB2, TP53, MAPK-RAS, PIK3, TGF-beta, NOTCH, ALK, FLT3, FGFR, WNT. Treatment selection, duration response, survival recorded. stratified based on their first-line therapy, either FOLFIRINOX (FFX) or gemcitabine/nab-paclitaxel (GA). present median time-to-first progression (PFS1) overall (OS) the presence absence in these pathways. The time-to-event endpoint was estimated by Kaplan-Meier method. Results: Of samples, 131 for PFS1; 57 received FFX, 60 GA. In FFX group, no pathway predicted PFS1 statistical significance. GA KIT (n = 10) showed improved vs. non-KIT mutated tumors (10.3 mos 6.2 mos, p 0.02). Similar improvement seen PIK3 25, 6.6 5.7, 0.02) FLT3 4, 13.1 6.2, 125 samples OS. 21) better OS (21.3 12.2 0.04), as did NOTCH 44, 15 12.3, < 0.01). trend toward (23.6 13, 0.3). had difference 8 KRAS WT; removing analysis not change results. Conclusions: this sample, (but FFX) Tumors an This similar analyses could identify potential drivers treatment response pancreatic tumors. [Table: see text]